Dinamarca - danès - Lægemiddelstyrelsen (Danish Medicines Agency)

glenmark arzneimittel gmbh - beclometasondipropionat - inhalationsspray, opløsning - 250 mikrogram/dosis

Unió Europea - danès - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Unió Europea - danès - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - vedligeholdelsesbehandling hos voksne patienter med moderat til svær kronisk obstruktiv lungesygdom (kol), der ikke er tilstrækkeligt behandlet ved en kombination af et inhaleret binyrebarkhormon og en langtidsvirkende beta2-agonist (for effekter på symptomer kontrol og forebyggelse af eksacerbationer se afsnit 5.

Unió Europea - danès - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - vedligeholdelsesbehandling hos voksne patienter med moderat til svær kronisk obstruktiv lungesygdom (kol), der ikke er tilstrækkeligt behandlet ved en kombination af et inhaleret binyrebarkhormon og en langtidsvirkende beta2-agonist (for effekter på symptomer kontrol og forebyggelse af eksacerbationer se afsnit 5.

Unió Europea - danès - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasonpropionat - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - airexar spiromax er indiceret til brug kun hos voksne i alderen 18 år og ældre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesygdom (kol)airexar spiromax er indiceret til symptomatisk behandling af patienter med kol med fev1.

Dinamarca - danès - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - fluticasonpropionat - inhalationspulver - 100 mikrogram/dosis

Dinamarca - danès - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - fluticasonpropionat - inhalationspulver - 250 mikrogram/dosis

Dinamarca - danès - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - fluticasonpropionat - inhalationspulver - 500 mikrogram/dosis

Dinamarca - danès - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fluticasonpropionat - inhalationspulver - 500 mikrogram/dosis

Dinamarca - danès - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - fluticasonpropionat - inhalationspulver - 50 mikrogram/dosis